In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Pfizer buys Angiosyn in deal based largely on milestones

Executive Summary

Pfizer is acquiring privately held Angiosyn (develops therapeutics that control angiogenesis) for a small up-front fee, while the majority of the payments on the deal--worth up to $527mm--are based on Angiosyn's successful development of drugs for an ophthalmic indication and a second undisclosed therapeutic area. (Strategic Transactions assumes the up-front payment to be $132mm and the rest in earn-outs.) Pfizer will also pay sales royalties.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Acquisition
    • Full Acquisition
    • Includes Earnout
    • Payment Includes Cash
    • Acquisition of Private Biotech

Related Companies

Advertisement
UsernamePublicRestriction

Register